Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade

Published:2017-03-07 Issue:1 Volume:3 Page:
ISSN:2056-5968
Container-title:Cell Discovery
language:en
Short-container-title:Cell Discov

Author:

Zhang Fei,Wei Hudie,Wang Xiaoxiao,Bai Yu,Wang Pilin,Wu Jiawei,Jiang Xiaoyong,Wang Yugang,Cai Haiyan,Xu Ting,Zhou Aiwu

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Genetics,Molecular Biology,Biochemistry

Link

http://www.nature.com/articles/celldisc20174.pdf

Reference55 articles.

1. Mullard A . New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov 2013; 12: 489–492.

2. Mellman I, Coukos G, Dranoff G . Cancer immunotherapy comes of age. Nature 2011; 480: 480–489.

3. Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–264.

4. Okazaki T, Honjo T . The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27: 195–201.

5. Carreno BM, Collins M . The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002; 20: 29–53.

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural trends in antibody-antigen binding interfaces: a computational analysis of 1833 experimentally determined 3D structures;Computational and Structural Biotechnology Journal;2024-12

2. β-glucan combined with Envafolimab and Endostar as immune rechallenge for metastatic non-small cell lung cancer;BMC Immunology;2024-09-14

3. Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a “shock and kill” strategy for ART-free virological control: a phase II single-arm study;Signal Transduction and Targeted Therapy;2024-09-09

4. Model-informed drug development of envafolimab, a subcutaneously injectable PD-L1 antibody, in patients with advanced solid tumors;The Oncologist;2024-07-09

5. Nanobody-liposomes as novel cancer vaccine platform to efficiently stimulate T cell immunity;International Journal of Pharmaceutics;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3